Month: February 2017

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who

BUHLMANN LabSense News: Winter 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the second edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News. Here you will also be able to access valuable resources, applications, and other newsworthy items specific to fields of in vitro diagnostics and scientific research. In this edition we

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.

Month: February 2017

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BUHLMANN LabSense News: Winter 2017 Edition

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US